What does the evidence say about Chia Seed Cardiometabolic Markers Randomized Trial?

The current Migaku evidence database contains 2 reusable source documents for Chia Seed Cardiometabolic Markers Randomized Trial. This answer focuses on benefits, uncertainty, and practical interpretation. - Background Obesity is a significant public health issue associated with various chronic diseases. [Karimi M (2024); evidence level 1] - This review aims to comprehensively analyze the available evidence on the effects of chia seeds on cardiometabolic indices in overweight populations through a meta-analysis. [Karimi M (2024); evidence level 1] - However, chia seed supplementation was associated with a significant reduction in C-reactive protein (CRP) (MD: - 1.18 mg/L, p 2 , p = 0.91), but a significant reduction in waist circumference (WC) (MD: - 2.82 cm, p 2 Conclusion Chia seed supplementation does not significantly impact most lipid profile parameters and glycemic markers. [Karimi M (2024); evidence level 1] - Research has indicated that chia seeds have the potential to improve cardiometabolic health. [Karimi M (2024); evidence level 1] - It is often associated with hormonal imbalance, metabolic disturbances, and reproductive complications, which together contribute to an elevated risk of long-term cardiometabolic disorders. [Singnale P (2026); evidence level 4] Evidence levels are sorting aids, not final clinical grades. Level 1 usually indicates systematic-review style evidence, level 2 indicates randomized trials or public-health guidance, and lower levels need more cautious wording. This page is educational. People with medical conditions, pregnancy, medication use, or unusual symptoms should ask a qualified clinician before changing supplements, medication, or treatment routines.